Explore the Agenda
8:00 am Check In & Registration
9:00 am Investment & Partnership Panel – Accelerating Innovation in Conjugate Therapeutics
Hear directly from VCs and pharma BD leaders on what data packages, formats, and strategies attract investment:
- What pharma wants: therapeutic index, MoA clarity, and early efficacy signals
- Pre-IND vs. Phase I: where investors draw the line on risk
- Collaboration models and platform licensing strategies
10:00 am Navigating the ADC Patent Landscape: Strategic Approaches to Taking Advantage of Key ADC Patent Expirations & Building ADC Patent Assets With & Without Traditional Payloads
- Analyzing the implications of traditional payload patent expiration on ADC development strategy
- Understanding opportunities for medicinal chemistry modifications to create novel IP around off-patent payloads
- Exploring strategic approaches to protecting novel ADC candidates and evaluating potential candidates against the patent landscape
10:30 am Deep Diving Into the Next Wave of ADC & XDC Design & Payload Innovation
- Breaking down the exciting landscape of novel drug conjugate design and mechanism of action
- Exploring emerging trends across drug conjugate design and targets
- Spotlighting novel conjugate innovation across multi payload ADCs, bispecific ADCs, and degrader conjugates
11:00 am Session Reserved for GBI Bio
11:15 am Morning Break & Networking
Beyond Oncology - Advancing Bioconjugates in Immunology, Inflammation & Neurology
11:45 am Engineered Antibodies to Improve Brain Delivery of Oligonucleotide
- Antibody-based "brain shuttles" can deliver therapeutic oligonucleotides to the brain, but the biophysical properties of payload can negatively affect pharmacokinetics
- Engineered antibody complexes with additional binders are used to mask the payload
- These engineered entities demonstrate improved specific targeting in cellular models, and improved PK and brain delivery in animal models
12:15 pm Looking Beyond Oncology: Investigating Development & Delivery of AOCs Against Neuromuscular Disorders
- Exploring the FORCE modular drug delivery approach to enable widespread distribution of AOCs and chemically diverse therapeutic payloads to muscle and the CNS
- Assessing clinical data from DYNE-101 ACHIEVE trial in patients with DM1 and DYNE-251 DELIVER trial against DMD
- Contextualising how the encouraging clinical data and preclinical efficacy in FSHD and Pompe models supports the potential of FORCETM and AOCs to address neuromuscular disorders with high unmet medical needs
12:45 pm Novel, Linkable TGF-b Inhibitor Payload Selectively & Safely Blocks Fibrotic Disease & Immune Suppression in Cancer Patients
- Developed first in class non-cytotoxic, linkable TGF-b inhibitor payload to selectively and safely block TGF-b, in an Antibody drug conjugate format
- SYN101 is a first in class immune cell targeted TGF-b therapy that restores immune function in cancer patients
- SYN303 is a myofibroblast targeted TGF-b therapy that blocks fibrosis and inflammation in a wide variety of fibrotic diseases
1:15 pm Lunch
Exploring Strategies for Unlocking Success with Immune- Stimulating Payloads
2:15 pm Preclinical Development of a Potent STING Agonist ADC
- STING is an innate, antiviral immune pathway that can be co-opted to elicit antitumor immunity but must be tightly controlled to avoid toxic systemic immune activation.
- We describe a novel, tumor-targeted STING agonist ADC that drives robust antitumor activity in a variety of preclinical murine tumor models.
- We discuss how drug-linker design, target antigen, as well as Fcγ receptor binding impact ADC activity.
2:45 pm Dual-Payload ADCs to Enhance Anti-Tumor Immune Response and Overcome Payload Resistance
- Utilizing an innovative cell-free platform to create site-selective, high DAR, novel dual-payload ADCs with favorable pharmacokinetics
- Showcasing dual-payload ADCs with superior preclinical in vitro and in vivo efficacy to overcome acquired single-payload resistance
- Demonstrating an immunostimulatory-cytotoxin dual-payload ADC with enhanced efficacy and therapeutic potential
3:15 pm BDC-4182: A Claudin 18.2-Targeting ISAC with Significantly Enhanced Immune Activity and Efficacy in Low Antigen Density Models
- Integrating saRNA and siRNA payloads into antibody conjugates
- Managing immunogenicity and safety considerations
- Identifying the next wave of oligonucleotide drug conjugate candidates